Advertisement

Radical Prostatectomy in Locally Advanced Prostate Cancer

  • Aldo Brassetti
  • Vito Pansadoro
Chapter

Abstract

Although in the prostate-specific antigen (PSA) era most of patients are diagnosed with a low-risk localized prostate cancer (PCa), still 10–30% of the screened men will have a locally advanced disease (clinical stage (cT) ≥3a) at presentation (Lowrance et al., BJU Int 109:1309–1314, 2012; Gözen et al., BJU Int 116:102–108, 2015). Considering the well-documented high risk of recurrence, these patients were historically ideal candidates for systemic therapies (Lowrance et al., BJU Int 109:1309–1314, 2012). Although a consensus regarding the best treatment option for these patients is still missing, most of them will undergo radiation combined with androgen deprivation therapy (ADT) (Widmark et al., Lancet 373:301–308, 2009; Roach et al., J Clin Oncol 26:585–591, 2008; Bolla et al., Lancet 360:103–106, 2002). However, it has been proven that patients harboring high-risk/locally-advanced PCa are those who will more likely benefit from active treatment. Their risk of recurrence and cancer-specific mortality (CSM), in fact, is the highest immediately after surgery but it substantially decreases over time, highlighting the curative efficacy of local treatment (Briganti et al., Urol Oncol 33:163.e7–e13, 2015).

References

  1. 1.
    Lowrance WT, Elkin EB, Yee DS, Feifer A, Ehdaie B, Jacks LM, et al. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int. 2012;109:1309–14.  https://doi.org/10.1111/j.1464-410X.2011.10760.x.CrossRefPubMedGoogle Scholar
  2. 2.
    Gözen AS, Akin Y, Ates M, Hruza M, Rassweiler J. Impact of laparoscopic radical prostatectomy on clinical T3 prostate cancer: experience of a single centre with long-term follow-up. BJU Int. 2015;116:102–8.  https://doi.org/10.1111/bju.12710.CrossRefPubMedGoogle Scholar
  3. 3.
    Widmark A, Klepp O, Solberg A, Damber J-E, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–8.  https://doi.org/10.1016/S0140-6736(08)61815-2.CrossRefPubMedGoogle Scholar
  4. 4.
    Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–91.  https://doi.org/10.1200/JCO.2007.13.9881.CrossRefPubMedGoogle Scholar
  5. 5.
    Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, et al. Natural history of surgically treated high-risk prostate cancer. Urol Oncol. 2015;33:163.e7–13.  https://doi.org/10.1016/j.urolonc.2014.11.018.CrossRefGoogle Scholar
  7. 7.
    Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU–ESTRO–SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.  https://doi.org/10.1016/j.eururo.2016.08.003.CrossRefPubMedGoogle Scholar
  8. 8.
    Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–62.  https://doi.org/10.1016/j.juro.2008.11.032.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472–9.  https://doi.org/10.1016/S1470-2045(06)70700-8.CrossRefPubMedGoogle Scholar
  10. 10.
    Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–8.  https://doi.org/10.1016/S0140-6736(05)67101-2.CrossRefPubMedGoogle Scholar
  11. 11.
    D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.CrossRefPubMedGoogle Scholar
  12. 12.
    Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28:1508–13.  https://doi.org/10.1200/JCO.2009.22.2265.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int. 2011;107:765–70.  https://doi.org/10.1111/j.1464-410X.2010.09594.x.CrossRefPubMedGoogle Scholar
  14. 14.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95:751–6.  https://doi.org/10.1111/j.1464-410X.2005.05394.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Reese AC, Cooperberg MR, Carroll PR. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol. 2010;184:114–9.  https://doi.org/10.1016/j.juro.2010.03.025.CrossRefPubMedGoogle Scholar
  16. 16.
    Gandaglia G, De Lorenzis E, Novara G, Fossati N, De Groote R, Dovey Z, et al. Robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally-advanced prostate cancer. Eur Urol. 2017;71:249–56.  https://doi.org/10.1016/j.eururo.2016.05.008.CrossRefPubMedGoogle Scholar
  17. 17.
    Xylinas E, Drouin SJ, Comperat E, Vaessen C, Renard-Penna R, Misrai V, et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. BJU Int. 2009;103:1173–1178.; discussion 1178.  https://doi.org/10.1111/j.1464-410X.2008.08208.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol. 2000;38:372–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110:1709–13.  https://doi.org/10.1111/j.1464-410X.2012.11372.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Carver BS, Bianco FJ, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006;176:564–8.  https://doi.org/10.1016/j.juro.2006.03.093.CrossRefPubMedGoogle Scholar
  21. 21.
    Leow JJ, Chang SL, Meyer CP, Wang Y, Hanske J, Sammon JD, et al. Robot-assisted versus open radical prostatectomy: a contemporary analysis of an all-payer discharge database. Eur Urol. 2016;70:837–45.  https://doi.org/10.1016/j.eururo.2016.01.044.CrossRefPubMedGoogle Scholar
  22. 22.
    Suardi N, Dell’Oglio P, Gallina A, Gandaglia G, Buffi N, Moschini M, et al. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. Urol Oncol. 2016;34:57.e1–7.  https://doi.org/10.1016/j.urolonc.2015.08.019.CrossRefGoogle Scholar
  23. 23.
    Gandaglia G, Abdollah F, Hu J, Kim S, Briganti A, Sammon JD, et al. Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments. J Endourol. 2014;28:784–91.  https://doi.org/10.1089/end.2013.0774.CrossRefPubMedGoogle Scholar
  24. 24.
    Raychaudhuri B, Cahill D. Pelvic fasciae in urology. Ann R Coll Surg Engl. 2008;90:633–7.  https://doi.org/10.1308/003588408X321611.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cornu J-N, Phé V, Fournier G, Delmas V, Sèbe P. Fascia surrounding the prostate: clinical and anatomical basis of the nerve-sparing radical prostatectomy. Surg Radiol Anat. 2010;32:663–7.  https://doi.org/10.1007/s00276-010-0668-7.CrossRefPubMedGoogle Scholar
  26. 26.
    Myers RP. Practical surgical anatomy for radical prostatectomy. Urol Clin North Am. 2001;28:473–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Church JM, Raudkivi PJ, Hill GL. The surgical anatomy of the rectum--a review with particular relevance to the hazards of rectal mobilisation. Int J Color Dis. 1987;2:158–66.CrossRefGoogle Scholar
  28. 28.
    Ger R. Surgical anatomy of the pelvis. Surg Clin North Am. 1988;68:1201–16.CrossRefPubMedGoogle Scholar
  29. 29.
    Sattar AA, Noël JC, Vanderhaeghen JJ, Schulman CC, Wespes E. Prostate capsule: computerized morphometric analysis of its components. Urology. 1995;46:178–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Ayala AG, Ro JY, Babaian R, Troncoso P, Grignon DJ. The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol. 1989;13:21–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Di Lollo S, Menchi I, Brizzi E, Pacini P, Papucci A, Sgambati E, et al. The morphology of the prostatic capsule with particular regard to the posterosuperior region: an anatomical and clinical problem. Surg Radiol Anat. 1997;19:143–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Tewari A, Peabody JO, Fischer M, Sarle R, Vallancien G, Delmas V, et al. An operative and anatomic study to help in nerve sparing during laparoscopic and robotic radical prostatectomy. Eur Urol. 2003;43:444–54.CrossRefPubMedGoogle Scholar
  33. 33.
    Villers A, Stamey TA, Yemoto C, Rischmann P, McNeal JE. Modified extrafascial radical retropubic prostatectomy technique decreases frequency of positive surgical margins in T2 cancers. Eur Urol. 2000;38:64–73.CrossRefPubMedGoogle Scholar
  34. 34.
    Kiyoshima K, Yokomizo A, Yoshida T, Tomita K, Yonemasu H, Nakamura M, et al. Anatomical features of periprostatic tissue and its surroundings: a histological analysis of 79 radical retropubic prostatectomy specimens. Jpn J Clin Oncol. 2004;34:463–8.  https://doi.org/10.1093/jjco/hyh078.CrossRefPubMedGoogle Scholar
  35. 35.
    Kourambas J, Angus DG, Hosking P, Chou ST. A histological study of Denonvilliers’ fascia and its relationship to the neurovascular bundle. Br J Urol. 1998;82:408–10.CrossRefPubMedGoogle Scholar
  36. 36.
    Secin FP, Karanikolas N, Gopalan A, Bianco FJ, Shayegan B, Touijer K, et al. The anterior layer of Denonvilliers’ fascia: a common misconception in the laparoscopic prostatectomy literature. J Urol. 2007;177:521–5.  https://doi.org/10.1016/j.juro.2006.09.028.CrossRefPubMedGoogle Scholar
  37. 37.
    Myers RP. Detrusor apron, associated vascular plexus, and avascular plane: relevance to radical retropubic prostatectomy--anatomic and surgical commentary. Urology. 2002;59:472–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Handley GH, Silbert BS, Mooney PH, Schweitzer SA, Allen NB. Combined general and epidural anesthesia versus general anesthesia for major abdominal surgery: postanesthesia recovery characteristics. Reg Anesth. 1997;22:435–41.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Centre of Robotic LaparoscopyVincenzo Pansadoro FoundationRomeItaly

Personalised recommendations